Scarica l'app Stockscreener
29.66
2.79%
-0.85
Pre-mercato:
28.14
-1.52
-5.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$30.51
Aprire:
$30.29
Volume 24 ore:
2.37M
Relative Volume:
1.31
Capitalizzazione di mercato:
$4.71B
Reddito:
$264.79M
Utile/perdita netta:
$-14.36M
Rapporto P/E:
-269.64
EPS:
-0.11
Flusso di cassa netto:
$-28.11M
1 W Prestazione:
+1.47%
1M Prestazione:
-4.94%
6M Prestazione:
+3.96%
1 anno Prestazione:
+1.54%
Intervallo 1D:
$29.64
$30.72
Intervallo di 1 settimana:
$28.69
$31.08
Portata 52W:
$25.28
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Nome
Tg Therapeutics Inc
Settore
Industria
Telefono
(212) 554-4484
Indirizzo
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
29.66 | 4.84B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2024-10-29 | Iniziato | TD Cowen | Buy |
| 2023-08-02 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-26 | Ripresa | Jefferies | Buy |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-01 | Iniziato | JP Morgan | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Iniziato | Evercore ISI | Outperform |
| 2020-01-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2018-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Ripresa | H.C. Wainwright | Buy |
| 2017-04-25 | Iniziato | Jefferies | Buy |
| 2017-03-06 | Reiterato | FBR & Co. | Outperform |
| 2016-10-06 | Ripresa | Brean Capital | Buy |
| 2016-05-27 | Iniziato | SunTrust | Buy |
| 2015-12-01 | Iniziato | FBR Capital | Outperform |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-19 | Reiterato | Brean Capital | Buy |
| 2014-12-11 | Reiterato | ROTH Capital | Buy |
| 2014-12-10 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
A Look at TG Therapeutics's Upcoming Earnings Report - Benzinga
TG Therapeutics faces earnings test as Briumvi growth accelerates - Investing.com India
TG Therapeutics (TGTX) Set to Announce Q4 Earnings with Positive Revisions - GuruFocus
FOMO Trade: Is TG Therapeutics Inc a top pick in the sectorWeekly Stock Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Goldman Sachs raises TG Therapeutics, Inc. (TGTX) target to $39 on 2026 guidance - MSN
Aug Rallies: Is TG Therapeutics Inc undervalued by DCF analysisWeekly Investment Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Analysis: A 50% Upside Potential In Biotech - DirectorsTalk Interviews
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Finviz
TG Therapeutics to Host Conference Call Discussing Q4 and Full Year 2025 Financial Results and 2026 Outlook - Quiver Quantitative
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update - marketscreener.com
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares - AOL.com
What are TG Therapeutics Inc.’s recent SEC filings showing2025 EndofYear Setup & Safe Capital Preservation Plans - mfd.ru
What is TG Therapeutics Inc.’s valuation compared to sectorDay Trade & Smart Swing Trading Alerts - mfd.ru
Persistent Asset Partners Ltd Sells 71,539 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
Will TG Therapeutics Inc. benefit from AI trendsForecast Cut & AI Enhanced Trading Signals - mfd.ru
TG Therapeutics, Inc. Announces the Publication of Long Term/Five-Year Data from the Ongoing Open-Label Extension of the Phase 3 Ultimate I and Ii Studies - marketscreener.com
5-year MS study: BRIUMVI patients average one relapse every 50 years - Stock Titan
Liquidity Mapping Around (TGTX) Price Events - Stock Traders Daily
Portfolio Shifts: Should you avoid TG Therapeutics Inc stock right now2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Analysis: A 55.89% Potential Upside in the Biotech Space - DirectorsTalk Interviews
What are TG Therapeutics Inc.’s growth leversJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - mfd.ru
TG Therapeutics, Inc. $TGTX Shares Bought by Public Sector Pension Investment Board - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Downgraded by Wall Street Zen to "Hold" - MarketBeat
TGTX Stock Price, Forecast & Analysis | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance - Insider Monkey
Should you avoid TG Therapeutics Inc. stock right now2025 Sector Review & Free Risk Controlled Daily Trade Plans - mfd.ru
Why TG Therapeutics Inc. (NKB2) stock gets analyst attentionTrade Entry Report & Community Supported Trade Ideas - mfd.ru
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
Should New BRIUMVI Data and MS Campaign Shift TG Therapeutics' (TGTX) Narrative on Commercial Execution? - Yahoo Finance
TG Therapeutics lights up Super Bowl with Christina Applegate MS campaign — retail sees 'huge win' - MSN
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win' - Stocktwits
MSFT Vs AMZN Vs GOOGL: Which Cloud Stock Is A Better Bet? - Stocktwits
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis - GlobeNewswire
Christina Applegate fronts new MS honesty campaign with TG Therapeutics - Stock Titan
TG Therapeutics Partners with Christina Applegate to Raise MS Awareness - intellectia.ai
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan - Finviz
TG Therapeutics presents BRIUMVI data at ACTRIMS forum By Investing.com - Investing.com Nigeria
TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally - MSN
TG Therapeutics Presents BRIUMVI Data at ACTRIMS Annual Meeting - Intellectia AI
TG Therapeutics presents BRIUMVI data at ACTRIMS forum - Investing.com
TG Therapeutics rises on new data for autoimmune therapy - TradingView
TG Therapeutics Presents New Data on BRIUMVI® at ACTRIMS 2026 Annual Forum - Quiver Quantitative
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - The Manila Times
Real-world and pediatric MS data put BRIUMVI under spotlight at ACTRIMS - Stock Titan
Tg Therapeutics Inc Azioni (TGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.52%
1.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):